Pluristyx announces license agreement with Humacyte for iPSCs

Pluristyx announced a license agreement with Humacyte. Humacyte has licensed Pluristyx’s clinical-grade PluriBank induced Pluripotent Stem Cell, or iPSC, line as starting materials for manufacturing insulin-producing cells for their BioVascular Pancreas product candidate, Pluristyx stated. “This partnership includes access to Pluristyx’s revolutionary panCELLa platform that enables the generation of ‘hypoimmune’ cells for clinical implantation… The License Agreement grants Humacyte access to Pluristyx’s PluriBank(TM) cell lines for application in their BioVascular Pancreas development program. Pluristyx is also performing custom clinical gene editing on the iPSC line to generate a universally applicable line for all patients. The BVP is designed to revolutionize type 1 diabetes treatment by enabling delivery and survival of insulin-producing islets inside the body. The Acellular Tissue Engineered Vessel and the BVP are investigational products and have not been approved for sale by the Food and Drug Administration or any international regulatory agency,” the company added. “The combination of Humacyte’s Acellular Tissue Engineered Vessel with insulin-producing cells derived from Pluristyx’s best-in-class iPSC lines brings us one step closer to curing insulin dependent diabetes,” said Dr Benjamin Fryer, Pluristyx’s CEO.